U.S. markets closed

OpGen, Inc. (OPGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5874-0.0350 (-5.62%)
At close: 04:00PM EDT
0.6407 +0.05 (+9.07%)
After hours: 07:50PM EDT

OpGen, Inc.

9717 Key West Avenue
Suite 100
Rockville, MD 20850
United States
240 813 1260

IndustryDiagnostics & Research
Full Time Employees91

Key Executives

NameTitlePayExercisedYear Born
Dr. Oliver Schacht Ph.D.CEO, Pres & Director600.2kN/A1971
Mr. Johannes BacherChief Operating Officer396.52kN/A1969
Mr. Albert WeberCFO & Corp. Sec.N/AN/A1963
Mr. Vadim SapiroChief Information OfficerN/AN/A1971
Mr. Michael FarmerVP of MarketingN/AN/AN/A
Ms. Faranak AtrzadehChief Marketing & Scientific Affairs OfficerN/AN/AN/A
Dr. G. Terrance Walker Ph.D.Sr. VP of R&DN/AN/A1959
Mr. Derek JoestingSr. VP of US SalesN/AN/AN/A
Dr. Arne MaternaMD & CEO of Ares Genetics GmbHN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Corporate Governance

OpGen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.